Homology Medicines Accounts Payables 2011-2026 | FIXX

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Homology Medicines

2025	2024	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
879 K	2.99 M	1.14 M	2.37 M	4.72 M	2.61 M	15.7 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
15.7 M	879 K	4.35 M

Quarterly Accounts Payables Homology Medicines

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
973 K	910 K	2.71 M	2.99 M	1.26 M	2.48 M	-	3.47 M	7.8 M	3.39 M	3.64 M	1.14 M	4.84 M	3.76 M	9.88 M	2.37 M	3.52 M	5.7 M	4.88 M	4.72 M	4.72 M	4.72 M	4.72 M	2.61 M	2.61 M	2.61 M	2.61 M	15.7 M	15.7 M	15.7 M	15.7 M	2.54 M	2.54 M	2.54 M	2.54 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
15.7 M	910 K	4.94 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
ACADIA Pharmaceuticals ACAD	16.2 M	$ 22.56	2.13 %	$ 3.74 B	USA
Acorda Therapeutics ACOR	13.4 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	1.61 M	-	-	$ 86.2 M	USA
I-Mab IMAB	570 M	-	-	$ 866 M	China
Akebia Therapeutics AKBA	21.2 M	$ 1.43	3.62 %	$ 368 M	USA
Allakos ALLK	1.76 M	-	-	$ 28.6 M	USA
Alnylam Pharmaceuticals ALNY	116 M	$ 327.25	2.42 %	$ 42.9 B	USA
AlloVir ALVR	1.28 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	1.58 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	1.74 M	-	-	$ 8.42 M	USA
Autolus Therapeutics plc AUTL	3.08 M	$ 1.49	9.56 %	$ 397 M	Britain
AVROBIO AVRO	27 K	-	1083.1 %	$ 745 M	USA
Advaxis ADXS	6.08 M	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	32.6 M	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	29.9 M	$ 4.18	1.21 %	$ 447 M	USA
Ayala Pharmaceuticals AYLA	4.08 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	10.6 M	$ 2.66	3.5 %	$ 16.7 M	USA
Brainstorm Cell Therapeutics BCLI	7.07 M	-	-2.5 %	$ 5.88 M	USA
Arcutis Biotherapeutics ARQT	12.5 M	$ 24.61	5.76 %	$ 3.13 B	USA
BeiGene, Ltd. BGNE	479 M	-	0.49 %	$ 251 B	Cayman-islands
Checkmate Pharmaceuticals CMPI	3.38 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	1.93 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Cabaletta Bio CABA	6.64 M	$ 3.09	0.65 %	$ 310 M	USA
CymaBay Therapeutics CBAY	3.83 M	-	-	$ 3.45 B	USA
Applied Genetic Technologies Corporation AGTC	2.91 M	-	-	$ 26.5 M	USA
Codiak BioSciences CDAK	1.84 M	-	-55.98 %	$ 2.15 M	USA
Avid Bioservices CDMO	20.7 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	3.61 M	-	-	$ 1.41 B	USA
AIkido Pharma AIKI	611 K	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	2.91 M	-	-45.71 %	$ 1.2 M	Canada
Checkpoint Therapeutics CKPT	6.09 M	-	-	$ 169 M	USA
Celldex Therapeutics CLDX	1.18 M	$ 32.41	3.38 %	$ 2.15 B	USA
Celsion Corporation CLSN	1.39 M	-	-6.63 %	$ 13.9 M	USA
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
Chimerix CMRX	2.85 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	2.61 M	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	8.77 M	$ 3.88	2.11 %	$ 261 B	Britain